Biodexa Pharmaceuticals Plc
BDRXHealthcare|Biotechnology|GB
$2.48
+0.07 (+2.88%)
DCF Value
$0.42
Tangible Book / Share
$0.19
Cash / Share
$0.17
Financials
Financial Snapshot
Market Cap
$231.2K
Enterprise Value
-$3.0M
Revenue (TTM)
$0.00
Net Income (TTM)
-$10.7M
Cash & Investments
$3.2M
Net Cash
$3.2M
Free Cash Flow (TTM)
-$18.5M
Operating CF (TTM)
-$17.7M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$3.2M
Quarterly Burn
$4.4M
Monthly Burn
$1.5M
Est. Runway
~0.7 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $17.6M | $13.2M | $2.3M | $10.9M | $7.5M | $10.1M | $2.8M | $6.0M | $1.7M | $8.5M | $3.2M | |
| Operating Cash Flow | -$13.1M | -$13.0M | -$13.4M | -$6.5M | -$9.3M | -$6.0M | -$7.0M | -$6.8M | -$12.3M | -$5.4M | -$17.7M | |
| Free Cash Flow | -$14.4M | -$13.7M | -$13.7M | -$6.8M | -$9.5M | -$6.3M | -$7.1M | -$7.1M | -$13.0M | -$5.4M | -$18.5M | |
| Capital Expenditure | -$1.3M | -$707.0K | -$244.0K | -$319.0K | -$209.0K | -$320.0K | -$62.0K | -$263.0K | -$774.0K | -$2.0K | -$783.2K | |
| Financing Cash Flow | $15.3M | $10.3M | -$6.5M | $18.7M | $3.1M | $8.8M | $47.0K | $10.2M | $8.6M | $12.8M | $16.9M |
R&D Spending
R&D (TTM)
$10.2M
R&D Intensity
—
R&D Growth vs Prior
+172.6%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $989.0K | $1.9M | $674.0K | $343.0K | $578.0K | $699.0K | $381.0K | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $7.7M | $9.8M | $9.4M | $7.8M | $16.1M | $4.7M | $5.1M | $4.1M | $5.4M | $3.7M | $10.2M | |
| R&D % of Revenue | 584.3% | 993.8% | 482.9% | 1163.6% | 4707.3% | 805.2% | 731.2% | 1067.5% | — | — | — | |
| SG&A | $3.2M | $4.4M | $4.4M | $4.2M | $5.0M | $2.9M | $4.5M | $4.3M | $3.8M | $4.8M | $8.3M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $989.0K | $1.9M | $674.0K | $343.0K | $578.0K | $699.0K | $381.0K | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $7.7M | $8.3M | $9.4M | $7.8M | $6.1M | $4.7M | $5.1M | $4.1M | $5.4M | $184.9K | $5.0M | |
| Gross Profit | -$6.4M | -$7.3M | -$7.4M | -$7.2M | -$5.7M | -$4.1M | -$4.4M | -$3.7M | -$5.4M | -$184.9K | -$5.0M | |
| R&D | $7.7M | $9.8M | $9.4M | $7.8M | $16.1M | $4.7M | $5.1M | $4.1M | $5.4M | $3.7M | $10.2M | |
| SG&A | $3.2M | $4.4M | $4.4M | $4.2M | $5.0M | $2.9M | $4.5M | $4.3M | $3.8M | $4.8M | $8.3M | |
| Operating Income | -$9.7M | -$11.8M | -$11.8M | -$11.3M | -$23.0M | -$7.0M | -$8.9M | -$8.0M | -$9.2M | -$8.3M | -$18.5M | |
| Interest Expense | $0.00 | $109.0K | $587.0K | $97.0K | $34.0K | $44.0K | $53.0K | $41.0K | $0.00 | $68.5K | $163.0K | |
| Pretax Income | -$8.4M | -$13.0M | -$12.4M | -$10.9M | -$23.5M | -$6.1M | -$8.5M | -$7.5M | -$6.0M | -$6.3M | -$10.9M | |
| Net Income | -$6.2M | -$11.7M | -$10.4M | -$10.1M | -$22.2M | -$5.5M | -$7.7M | -$7.1M | -$5.7M | -$6.2M | -$10.7M | |
| EPS (Diluted) | -592694.97 | -317756.92 | -234243.03 | -28076.46 | -26567.82 | -3729.27 | -3816.54 | -55.71 | -2.96 | -0.32 | -1.36 | |
| EBITDA | -$5.3M | -$10.6M | -$10.7M | -$9.5M | -$22.2M | -$5.7M | -$8.1M | -$7.2M | -$8.9M | -$8.1M | -$18.1M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 2.48 | 27.43 | 18.66 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.6M | $13.2M | $2.3M | $10.9M | $7.5M | $10.1M | $2.8M | $6.0M | $1.7M | $8.5M | $3.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $22.3M | $18.6M | $5.6M | $13.7M | $9.3M | $11.8M | $4.7M | $7.0M | $8.8M | $12.4M | $6.6M | |
| Total Assets | $56.7M | $49.2M | $20.4M | $30.9M | $9.8M | $12.9M | $5.5M | $10.5M | $14.8M | $18.1M | $12.6M | |
| Total Current Liabilities | $9.3M | $8.4M | $2.5M | $5.7M | $3.0M | $1.8M | $1.9M | $5.6M | $5.0M | $6.1M | $2.8M | |
| Long-Term Debt | $1.6M | $6.2M | $714.0K | $4.8M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $11.0M | $14.5M | $3.5M | $11.3M | $3.1M | $2.5M | $2.4M | $5.9M | $6.5M | $6.8M | $3.1M | |
| Stockholders' Equity | $45.7M | $34.7M | $16.9M | $19.6M | $6.7M | $10.5M | $3.2M | $4.7M | $8.3M | $11.4M | $9.6M | |
| Retained Earnings | -$59.1M | -$74.7M | -$89.7M | -$99.8M | -$122.4M | -$127.8M | -$135.3M | -$144.8M | -$150.4M | -$102.6M | -$104.0M |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$13.1M | -$13.0M | -$13.4M | -$6.5M | -$9.3M | -$6.0M | -$7.0M | -$6.8M | -$12.3M | -$5.4M | -$17.7M | |
| Capital Expenditure | -$1.3M | -$707.0K | -$244.0K | -$319.0K | -$209.0K | -$320.0K | -$62.0K | -$263.0K | -$774.0K | -$2.0K | -$783.2K | |
| Free Cash Flow | -$14.4M | -$13.7M | -$13.7M | -$6.8M | -$9.5M | -$6.3M | -$7.1M | -$7.1M | -$13.0M | -$5.4M | -$18.5M | |
| Investing Cash Flow | -$1.2M | -$1.5M | $9.0M | -$3.8M | $2.6M | -$278.0K | -$220.0K | -$265.0K | -$598.0K | -$658.3K | -$1.3M | |
| Financing Cash Flow | $15.3M | $10.3M | -$6.5M | $18.7M | $3.1M | $8.8M | $47.0K | $10.2M | $8.6M | $12.8M | $16.9M | |
| Issuance of Stock | $0.00 | $5.7M | $0.00 | $14.1M | $9.7M | $9.0M | $243.0K | $10.4M | $8.3M | $13.4M | $21.9M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$239.0K | $4.7M | -$5.9M | $3.9M | -$6.2M | -$215.0K | -$178.0K | -$188.0K | $245.0K | -$696.0K | -$297.2K | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | -$34.0K | -$404.0K | $89.0K | $123.0K | $28.0K | $283.0K | $170.0K | $230.0K | |
| Net Change in Cash | $1.4M | -$4.4M | -$10.9M | $8.6M | -$3.4M | $2.5M | -$7.2M | $3.1M | -$4.3M | $7.0M | -$439.4K |
Dilution Tracker
Shares outstanding grew 2561107.6% over 5 years — significant dilution
Shares Outstanding
117M
5-Year Share Growth
+2561107.6%
Stock Issuance (TTM)
$21.9M
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 2.48 | 27.43 | 18.66 | |
| Change vs Prior % | — | 44.4% | 18.5% | 494.8% | 133.8% | 88.0% | 22.7% | 6293.7% | 1468.1% | 1007.7% | -32.0% | |
| Stock Issuance | $0.00 | $5.7M | $0.00 | $14.1M | $9.7M | $9.0M | $243.0K | $10.4M | $8.3M | $13.4M | $21.9M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | -$34.0K | -$404.0K | $89.0K | $123.0K | $28.0K | $283.0K | $170.0K | $230.0K |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | -484.3% | -742.2% | -382.9% | -1063.6% | -1669.1% | -705.2% | -631.2% | -967.5% | — | — | — | |
| Operating Margin % | -729.6% | -1190.7% | -609.6% | -1679.2% | -6717.2% | -1210.7% | -1277.8% | -2103.4% | — | — | — | |
| Net Margin % | -465.7% | -1183.5% | -535.0% | -1496.3% | -6469.1% | -944.6% | -1095.3% | -1858.0% | — | — | — | |
| EBITDA Margin % | -400.8% | -1072.7% | -552.3% | -1415.6% | -6477.8% | -979.1% | -1157.7% | -1879.5% | — | — | — | |
| FCF Margin % | -1090.9% | -1381.2% | -706.6% | -1010.1% | -2772.6% | -1094.8% | -1017.2% | -1860.6% | — | — | — | |
| ROE % | -13.5% | -33.8% | -61.3% | -51.6% | -330.3% | -52.2% | -242.1% | -151.3% | -68.8% | -54.8% | -42.4% | |
| ROA % | -10.9% | -23.8% | -50.7% | -32.6% | -226.0% | -42.3% | -138.6% | -67.2% | -38.8% | -34.4% | -35.1% | |
| ROIC % | -14.8% | -25.8% | -53.9% | -36.9% | -309.9% | -55.8% | -212.8% | -147.4% | -85.1% | -67.3% | -95.8% | |
| R&D / Revenue % | 584.3% | 993.8% | 482.9% | 1163.6% | 4707.3% | 805.2% | 731.2% | 1067.5% | — | — | — |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -3.8% | -25.2% | 96.0% | -65.2% | -49.1% | 68.5% | 20.9% | -45.5% | -100.0% | 0.0% | |
| Gross Profit | -591.0% | -14.6% | -1.1% | 3.4% | 20.1% | 28.8% | -8.2% | 16.5% | -47.5% | 96.6% | |
| Operating Income | 4.4% | -22.0% | -0.3% | 4.2% | -103.6% | 69.6% | -27.6% | 10.3% | -14.8% | 10.1% | |
| Net Income | 39.0% | -90.0% | 11.4% | 2.7% | -120.0% | 75.4% | -40.2% | 7.5% | 19.1% | -9.0% | |
| EPS (Diluted) | -38.0% | 46.4% | 26.3% | 88.0% | 5.4% | 86.0% | -2.3% | 98.5% | 94.7% | 89.2% | |
| Operating Cash Flow | -5.4% | 1.0% | -3.8% | 51.8% | -43.3% | 35.4% | -17.3% | 3.1% | -79.6% | 56.0% | |
| Free Cash Flow | -8.2% | 5.4% | -0.2% | 50.3% | -39.7% | 33.5% | -12.4% | 0.3% | -83.9% | 58.6% | |
| R&D Expense | -11.3% | 27.2% | -4.8% | -16.2% | 105.9% | -71.2% | 9.8% | -20.4% | 33.7% | -31.4% | |
| SG&A Expense | 20.8% | 36.7% | -0.9% | -5.2% | 19.1% | -40.6% | 54.2% | -4.4% | -12.6% | 27.5% | |
| Total Assets | -11.5% | -13.2% | -58.5% | 51.1% | -68.2% | 31.5% | -57.2% | 90.8% | 40.2% | 22.8% | |
| Book Value / Share | -23.3% | -46.6% | -59.0% | -80.4% | -85.3% | -17.2% | -75.3% | -97.7% | -88.7% | -87.6% | |
| Debt | 10.7% | 203.3% | -80.9% | 385.8% | -95.7% | 194.6% | -18.5% | -25.6% | 56.7% | -91.6% | |
| Diluted Shares | 27.1% | 41.9% | 19.1% | 490.9% | 133.7% | 88.0% | 22.7% | 6291.4% | 1468.1% | 1007.7% |
Valuation
P/E (TTM)At Loss
P/S0.00
10Y Low / Med / High3889.42 / 32665.95 / 68377.72
P/B3.62
10Y Low / Med / High162.36 / 974.31 / 3491.15
EV/EBITDA0.33
EV/Revenue0.00
10Y Low / Med / High3888.86 / 32659.22 / 68356.48
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.42
Tangible Book / Share
$0.19
Net Current Assets / Share
$0.03
Graham Net-Net
$0.14
Cash / Share
$0.17
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -3017.72 | -1561.64 | -414.96 | -1481.02 | -824.26 | -3328.40 | -682.75 | -378.25 | -436.67 | -210.59 | -46.36 | |
| P/S Ratio | 62009.20 | 32665.95 | 3889.42 | 28272.29 | 68377.72 | 43243.48 | 9210.99 | 8734.72 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 1794.20 | 931.67 | 445.39 | 974.31 | 3491.15 | 2391.28 | 2036.21 | 711.40 | 385.21 | 162.36 | 3.62 | |
| EV/EBITDA | -15470.15 | -3044.58 | -704.09 | -1996.72 | -1055.24 | -4415.17 | -795.39 | -463.96 | -358.28 | -227.62 | 0.33 | |
| EV/Revenue | 61997.52 | 32659.22 | 3888.86 | 28265.10 | 68356.48 | 43227.41 | 9207.83 | 8720.27 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-13.58
Distress
Piotroski F-Score
0
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $5.7K | $2.8K | $0.00 |
| Net Income | -$13.4K | -$13.4K | $0.00 |
| EPS | $-0.00 | $-0.00 | $0.00 |
| # Analysts (EPS) | 1 | 1 | 0 |